Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biliary Drainage Plus HAIC Versus Biliary Drainage Plus BSC in Locally Advanced Perihilar Cholangiocarcinoma
NCT05024513Phase 2Completed
- Sponsor
- Peking University
- Start
- Nov 2021
- Primary completion
- Oct 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin and fluorouracil in perihilar cholangiocarcinoma (PHC) (2 arms), sponsored by Peking University. Primary endpoint: Overall survival at 1 year. Started Nov 2021; status: completed.
02
Drugs
oxaliplatinfluorouracil
03
Conditions
perihilar cholangiocarcinoma (PHC)
Beyond the preview
Go deeper on NCT05024513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024513.